Back to top

pharmaceuticals: Archive

Zacks Equity Research

AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review

AstraZeneca (AZN) announces acceptance of BLA seeking approval for trastuzumab deruxtecan in metastatic breast cancer by the FDA. The FDA also grants priority review.

AZN ABBV RHHBY GSK

Kinjel Shah

Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow

FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3

JNJ BAYRY ABBV LLY AZN AGN RHHBY

Zacks Equity Research

Factors Setting the Tone for Novartis' (NVS) Q3 Earnings

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.

PFE MRK NVS GILD

Nalak Das

5 Dow Stocks Poised to Beat on Earnings This Month

Despite severe market volatility, the Dow is still in positive territory with a gain of 15.9% year to date. This is an excellent performance after a disappointing 2018.

MRK BA AAPL UTX PG

Zacks Equity Research

Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.

ABBV NVS GSK INCY

Zacks Equity Research

Lilly's Pancreatic Cancer Candidate Fails in Phase III Study

Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.

LLY CELG TYME NCNA

Zacks Equity Research

Roche Posts Solid Sales for First 9 Months of '19, Ups View

Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.

RHHBY NVS AMGN ONCE

Zacks Equity Research

Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.

PFE LLY AMGN GILD

Zacks Equity Research

New Strong Sell Stocks for October 17th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

ARCB CVCY BGS EGRX TS

Swayta Shah

4 Stocks With Upgraded Broker Ratings to Buy Right Away

When brokers upgrade a stock, one can rely on their judgment. Nonetheless, one should also take into account some other factors to ensure steady returns.

BMY LOW VMC ACM

Mark Vickery

Top Stock Reports for Johnson & Johnson, Boeing & Pfizer

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Boeing (BA) and Pfizer (PFE).

QCOM PFE PBR MUFG JNJ BA

Zacks Equity Research

KalVista Pharmaceuticals Enters Oversold Territory

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

KALV

Kinjel Shah

Allergan (AGN) Shareholders Approve Acquisition by AbbVie

Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

ABBV AGN RVNC EOLS

Zacks Equity Research

J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

FDA approves Johnson & Johnson's (JNJ) Xarelto to prevent blood clots in hospitalized acutely ill medical patients.

BAYRY SNY BMY JNJ

Zacks Equity Research

J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View

J&J (JNJ) comes up with encouraging third-quarter 2019 results.

ABBV MRK JNJ TEVA

Mark Vickery

Q3 Results Begin: Can We Avoid an Earnings Recession?

Results from JPM, JNJ help paint the picture whether Q3 will bear out better than expected.

JPM JNJ

Zacks Equity Research

7 Value Price-to-Sales Stocks Poised to Fetch Strong Gains

A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.

GBX PAM SNY AZZ NPO INN GDOT

Zacks Equity Research

J&J (JNJ) Beats Q3 Earnings & Sales, Shares Rise

J&J (JNJ) beats estimates for earnings and sales in the third quarter of 2019 and raises 2019 guidance.

JNJ

Mark Vickery

Top Analyst Reports for Intel, Oracle & Novo Nordisk

Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Oracle (ORCL) and Novo Nordisk (NVO).

OXY ORCL NVO INTC COP AMD

Christopher Vargas

Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors

Johnson & Johnson (JNJ) is set to report their third quarter results as pending lawsuits loom over the company.

WFC AGN JNJ ENDP

Zacks Equity Research

Aclaris Divests Rhofade to EPI Health for $55M, Shares Up

Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.

AGN DERM RIGL ACRS

Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

NVO PFE NVS JNJ GSK

Zacks Equity Research

Lilly Gets FDA Approval for New Oral Tablets for Migraine

Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.

LLY PFE AMGN TEVA

Zacks Equity Research

Roche Announces Positive Late-Stage Data on Rituxan in PV

Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.

NVS RHHBY BMY AMGN

Zacks Equity Research

Moving Average Crossover Alert: Sage Therapeutics

Sage Therapeutics could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

SAGE